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Abstract 
BACKGROUND: Renal osteodystrophy is a major complication among dialysis patients that can lead to muscle 
weakness, and bone pain and fractures by minor trauma. In the present study, the frequency of these symptoms 
and status of blood markers among dialysis patients are discussed.  
METHODS: In a crass-sectional study, blood sample was obtained from 82 hemodialysis patients for calcium (Ca), 
phosphorus (P), alkaline phosphatase (ALP), and parathyroid hormone (PTH) level measurement. Radiography of 
the right hand was performed for 57 patients. Data analysis was performed via SPSS by using chi-square test, 
Fisher’s exact test, and Pearson correlation coefficient. 
RESULTS: The prevalence of osteodystrophy among dialysis patients was 72% (59 patients), including 29 patients 
with high bone turnover and 30 patients with adynamic bone disease. Moreover, 24 patients (29.3%) were 
hypocalcaemic and 25 patients (30.5%) were hypercalcemic. In addition, 25 (30.5%) patients had 
hyperphosphatemia. In the present study, 82 patients, 40 male (48.8%) and 42 female (51.2%), were recruited. 
Patients’ mean age ± standard deviation was 55.77 ± 14.99. There was a relation between increase in age and 
adynamic bone disease (P = 0.004). Calcium level had a significant association with radiologic manifestation of 
renal osteodystrophy (P = 0.007). PTH levels had moderate correlation with ALP level (r = 0.55). 
CONCLUSION: In the present study, there was a relation between age and adynamic bone disease; meaning that by 
increasing of age, the prevalence of adynamic bone disease also increased. There was a strong positive correlation 
between PTH and ALP. 
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Introduction1 
Renal osteodystrophy is a chronic kidney 
disease-mineral and bone disorder (CKD-MBD) 
which occurs due to renal failure. This disorder 




is a direct result of electrolyte abnormalities and 
endocrine disorders that accompany elevated 
serum phosphate levels, low or normal serum 
calcium, and parathyroid function stimulation.1 
The disruption is divided into two groups based 
on metabolic bone status; high exchange bone 
disease [high parathyroid hormone (PTH)] and 
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adynamic bone disease.2 A sample of high 
exchange bone disease is osteitis fibrosa which is 
developed due to high levels of PTH and 
manifests as pain and fragile bones. Other 
examples of disease with low bone turnover are 
adynamic bone disease (ABD) and osteomalacia. 
The cause of adynamic bone disease is not fully 
known; however, it is known that, diabetes, 
medications, and dialysis solutions with high 
concentrations play a role in its creation. In 
adynamic disease, the number of osteoblasts and 
osteoclasts are also reduced. The risk of bone 
fractures in adynamic patients is high.3  
Osteodystrophy is most common in dialysis 
patients. These patients suffer from bone pains, 
increased incidence of bone fracture and 
deformity, myopathy, muscular pain, and tendon 
rupture.4 This disease is associated with disability 
and reduced quality of life.5,6 In developing 
countries, the prevalence of this disease varies 
from 33.3% in Egypt to 81% in Brazil.7  
Most researchers use PTH, total alkalin 
phosphatase (ALP), calcium, and phosphorus as 
replacement for bone biopsy which is a gold 
standard diagnosis.8 PTH measurement is a 
suitable screening instrument for differential 
diagnosis of high bone exchange (osteitis fibrosa) 
and adynamic bone disease.5 Measuring PTH and 
ALP increases the accuracy of disease diagnosis.9 
Renal osteodystrophy manifestations in plain 
radiography include subchondral resorption of 
bone, soft tissue calcification osteopeny, amyloid 
repletion, and fracture.10 
The present study is designed and conducted 
for investigating renal osteodystrophy in 
hemodialysis patients. 
Materials and Methods 
In a crass-sectional study, blood sample was 
obtained from 82 hemodialysis patients for Ca, P, 
ALP, and PTH levels measurement. The patient's 
blood samples were sent to the laboratory of 
Tovhid Hospital. In this study, PTH levels above 
300 pg/ml show high exchange bone disease and 
PTH levels below pg/ml represent adynamic 
bone disease. The normal amount of calcium was 
considered to be 8.4-9.5 mg/dl, of phosphorus 
3.5-5.5 mg/dl, and of PTH was 100-300 pg/ml. 
Radiography of the right hand, including 
wrist, hand, was performed for 57 patients and 
results were interpreted by one radiologist. 
Radiological manifestation is positive in case of 
presence of at least 1 of these findings: 
disseminated demineralization of bones; 
osteolytic lesions; osteosclerosis; bone resorption; 
soft tissue calcification; osteopenia; amyloid 
deposition; and fracture predisposition.  
A checklist including demographic data, 
duration of disease, frequency of dialysis per 
week, and radiography reports was completed. 
Data analysis was performed via SPSS for 
Windows (version 16; SPSS Inc., Chicago, IL, 
USA) by using chi-square test, Fisher’s exact test, 
and Pearson correlation coefficient. 
Results 
The prevalence of osteodystrophy among dialysis 
patients was 72% (59 patients), including 29 
patients with high exchange bone disease, and 30 
patients with adynamic bone disease. In addition, 
23 patients (28%) had normal PTH. 
In the present study, 82 patients, 40 male 
(48.8%) and 42 female (51.2%), were recruited. 
Patients’ mean age ± standard deviation was 
55.77 ± 14.99 (range: 16-91 years). The largest and 
smallest age groups were 61-70 years (26.8%) and 
below 40 years (14.6%), respectively. During the 
study, 25 patients died. The frequency of dialysis 
for most of the patients (50 patients; 61%) was 
three times per week, 9.8% of patients had 
dialysis once a week. Moreover, 29 patients 
(35.4%) had PTH levels above 300 pg/ml that 
indicate high bone exchange disease. 
Normal PTH range was observed in 23 
patients (28%). In addition, 30 patients (36.6%) 
had a PTH level of below 100 pg/ml that 
indicates adynamic bone disease. There was a 
relation between increase in age and adynamic 
bone disease (P = 0.004) (Table 1). 
In terms of Ca levels, 24 patients (29.3%) were 
hypocalcaemic, 33 patients (40.2%) were normal, 
and 25 patients (30.5%) were hypercalcemic. In 
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terms of P levels, 25 patients (30.5%) had 
hyperphosphatemia, 57 patients (69.5%) were 
normal, and none of the patients had low 
phosphorus. 
Radiography of the wrist was performed for 57 
patients. The mean levels of calcium, alkaline 
phosphatase, and parathyroid hormone were not 
significantly different between the two groups of 
positive and negative radiological manifestations. 
However, the mean level of phosphorus was 
significantly different between the two groups  
(P < 0.05) (Table 2). However, Ca and P had no  
association with positive radiologic manifestation 
based on Fisher’s exact test (P > 0.05) (Table 3). 
PTH levels had moderate correlation with ALP 
level (r = 0.55). 
Discussion 
The prevalence of renal osteodystrophy based on 
PTH level was 72%, which consisted of 35.4% 
high bone exchange disease and 36.6% adynamic 
bone disease. In a study, the prevalence of renal 
osteodystrophy, high bone exchange disease, 
 








No (%) P 
Sex    
0.201 Man 15 (37.5) 14 (35.0) 11 (27.5) 
Woman 14 (33.3) 9 (21.4) 19 (45.2) 
Age    
0.004 < 40 y 9 (75.0) 2 (16.7) 1 (8.3) 41-60 15 (41.7) 9 (25.0) 12 (33.3) 
> 60 y 5 (14.7) 12 (35.3) 17 (50.0) 
Dialysis frequency    
0.483 Once per week 1 (12.5) 1 (12.5) 6 (75.0) Twice per week 6 (25.0) 9 937.5) 9 (37.5) 
Three times per week 22 (44.0) 13 (26.0) 15 (30.0) 
Radiologic manifestation    
0.902 Positive 6 (31.6) 6 (31.6) 7 (36.8) 
Negative 14 (31.8) 12 (31.6) 12 (31.6) 
 






No (%) P 
Calcium   
0.70 Positive 8 (42.1) 11 (57.9) 
Negative 14 (36.8) 24 (63.2) 
Phosphorus   
0.22 Positive 8 (42.1) 11 (57.9) 
Negative 10 (26.3) 28 (73.7) 
 
Table 3. Mean of blood indicators among hemodialysis patients based on radiologic manifestations 
Indicators Radiologic 
manifestations No Mean t P 
PTH Positive 19 320.95 0.672 0.18 Negative 38 389.24 
ALP Positive 19 345.74 0.101 0.72 Negative 38 339.42 
Ca Positive 19 8.88 0.090 0.90 Negative 38 8.90 
P Positive 19 5.55 1.635 0.02 Negative 38 5.13 
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 and adynamic bone disease were 55.3%, 28.1%, 
and 27.1%, respectively; these results are in 
accordance with the present study.11 In another 
study, total prevalence, and the prevalence of 
high bone exchange disease and adynamic bone 
disease were 87%, 45%, and 42%, respectively; 
this is higher than our study findings 
considering the proportion of the two diseases.12 
In the present study, we did not find any 
relation between sex and renal osteodystrophy. 
However, in the study by Gupta, female gender 
had association with renal osteodystrophy.13 
This difference in findings might be because of 
the small sample size of our study. Regarding 
age, adynamic bone disease increased along 
with increase in patients’ age (P = 0.004). This 
finding was in agreement with the study by 
Hernandez et al.14 
Considering calcium level, 29.4% of patients 
were hypocalcemic and 30.4% were 
hypercalcemic, which is in accordance with the 
study by Lye and Lee in which the prevalence of 
renal osteodystrophy was 24.4%.15 In the present 
study, 30.5% of patients were hyperphosphatemic, 
but there were no hypophosphatemic patients, 
which is reasonable considering the nature of 
chronic renal failure. However, in the study of Lye 
and Lee, the prevalence of renal osteodystrophy 
was higher (75.4%). This can explain the relative 
efficiency of chelation therapy in our patients and 
effect of phosphorus chelator treatment in our 
patients. In an Indonesian study, 61% of the 
patients were hypocalcemic and 10% were 
hypercalcemic.16 In another study, hypocalcaemia 
was associated with dialysis frequency and 
efficiency of dialysis.17 In the present study, 
phosphorus level had no association with PTH 
level; this is in agreement with the results of the 
study conducted in Gorgan.18  
Among the 57 candidates on whom hand 
radiography was performed, 23.2% had 
radiologic manifestations. This rate was 26% in 
the study by Gupta13, 94% in the study by 
Lacativa et al.19, and 3.35% in the study by 
Odenigbo et al.20 This difference might be 
because of ethnic variations and imaging 
techniques. 
A limitation of our study that reduced the 
prevalence of renal osteodystrophy was lack of 
access to digital radiography with higher quality 
and clearer radiographs. Radiologic findings in 
our study are consistent with the study by 
Odenigbo et al.20, but are not in accordance with 
the study by Lacativa et al.19 There was no 
significant relation between dialysis frequency 
and renal osteodystrophy which is not in 
agreement with the study by Lugon et al., this 
may be related to sample size.17 In our study, the 
mean blood level of ALP, PTH, and Ca were 320 
Iu/I, 372 pg/ml, and 8.95 mg/dl, respectively; 
this is in accordance with the studies by Nouri 
Majelan and Sanadgol, and Buargub et al.1,11 
There was a strong positive correlation 
between ALP and PTH that is similar to the 
results of studies by Nouri Majelan and 
Sanadgol, and Couttenye et al.1,21 This is a 
valuable finding in that it makes it possible to 
use ALP instead of PTH in medical centers 
which do not have access to PTH measurement 
for renal osteodystrophy patients. 
In our study, PTH level for high bone 
exchange disease was higher than 300 pg/ml. 
Based on this range, the prevalence of renal 
osteodystrophy was 35.4%. In the study by 
Atsumi et al., the prevalence of renal 
osteodystrophy was also 35%.22 
We had one limitation in this study; we were 
not able to perform drug assessment accurately 
because of irregular drug taking by patients.  
In the present study, there was a high 
prevalence of renal osteodystrophy 
(approximately two-thirds of patients). With 
increase in age, the prevalence of adynamic type of 
osteodystrophy (PTH levels below 100 pg/ml) 
increased and high exchange bone disease 
decreased. This finding shows that more attention 
should be paid to adynamic osteodystrophy in the 
elderly and high exchange bone disease and its 
treatment in younger patients. 
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